[374] DAYTWO PERSONALIZED NUTRITION BASED ON YOUR GUT MICROBIOME

Amir Golan[1], Yifat Robshitz[1], [1] Daytwo

DayTwo

Investment Rational

- DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition using artificial intelligence and machine learning on microbial genomics, human traits and disease.
- Science driven company with top Microbiome and computational biology scientists based on extensive research done at the Weizmann institute and the Mayo Clinic, backed by investment from J&J.

Business Strategy

Personalized nutrition recommendations for normalizing blood glucose levels) both direct to consumer & B2B2C via Health Practitioners (physicians, dietitians, diabetes educators) is commercially available in US and IL

- Main Focus: People with Diabetes/Prediabetes
- Partners such as Caregivers and Insured employers who can help to scale
- Long Term Strategy will expand current product to additional populations & base additional products on the microbiome platform

Core Technology

- 5 years and $5M of investment by Weizmann scientists, and thousands of clients help us to develop the **Big Data platform** and **algorithm** that predicts human metabolic phenotypes based on the microbiome.
- AI & ML algorithm that predicts PPGR and provide suggested recommended meals

Product Profile/Pipeline

Current product: Personalized nutrition recommendations for normalizing blood glucose levels and weight loss based on the microbiome"

- Product continuously populates the biggest microbiome database in the world
- Product pipeline: Using AI on our unique microbiome dataset to provide
- Personalized nutritional and lifestyle recommendations for improving gut health
- Diagnostics based on microbiome
- Therapeutics based on microbiome

What's Next?

Discussions with regulators aiming to become the “standard of care” for patients with Diabetes

- Microbiome as a Platform:

·Nutrition recommendations for changing microbiome towards 'healthy gut'
Probiotics - identifying the missing bacteria in people to add them back in
·Diagnostics Early indications in the microbiome for disease
· Therapeutics - using identified connections between microbiome and disease to provide leads to drug development